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A disintegrin andmetalloproteinases (ADAMs) are members of a new gene familyof transmembraneand secreted proteins, which
belong to the zinc proteinase superfamily. These molecules are inv o l v e di nv a r i o u sb i o l o g i c a le v e n t ss u c ha sc e l la d h e s i o n ,c e l l
fusion, cell migration, membrane protein shedding, and proteolysis. Growing evidence now attests to the potential involvement
of ADAMs proteinases in diverse processes such as skin wound healing, inﬂammation, pigmentation, tumor development, cell
proliferation, and metastasis.This paper focuses on the roles of ADAMs proteinases in a wide variety of skin diseases.
1.Introduction
Adisintegrin and metalloproteinases (ADAMs)are members
of a new gene family of transmembrane and secreted pro-
teins, which belong to the zinc protease superfamily. These
moleculesareinvolvedinvariousbiologicalprocessessuchas
cell adhesion, cell fusion, cell migration, membrane protein
shedding, and proteolysis. It has become clear in recent
years that ADAMs proteinases have important roles in skin
homeostasis and in skin diseases, and the signaling cascades
involved are gradually being identiﬁed [1, 2].
Many transmembrane proteins are processed by one or
several proteolytic steps to their biologically active forms
[1, 2]. Examples include growth factors such as epidermal
growth factor (EGF), heparin-binding EGF-like growth fac-
tor (HB-EGF) and transforming growth factor-α (TGF-α),
and cytokines such as tumor necrosis factor-α (TNF-α), all
ofwhich aresynthesized asprecursorproteinsthatneedtobe
cleavedtogain their functional activity. In addition,there are
a number ofcell surface receptorsthat undergocleavagenear
the transmembrane domain, a process called ectodomain
shedding [1, 2]. These include the TNF-α receptor, CD44,
L-selectin and KIT. The soluble, released ectodomains of
those receptors may be part of their downmodulation in
response to ligand activation and/or those fragments may
have functions of their own.
In this paper, we discuss the implicationsof ADAMspro-
teinases in several physiological and pathological functions
in skin tissue and their roles in various skin diseases.
2.Structureand Functionof ADAMs
Proteinases
There are two distinct groups in the ADAMs family:
the membrane-anchored ADAMs and the secreted-type
ADAMTS (ADAM with thrombospondin motifs), which are
not discussed in this paper. Each member of the ADAMs
family contains common domains, including the propep-
tide, metalloproteinase, disintegrin, cysteine-rich, EGF-like
(though this is absent in ADAM10 and ADAM17), trans-
membrane and cytoplasmic domains (Figure 1). Although
the structure of ADAMs and ADAMTS proteinases is closely
related, ADAMTS molecules are characterized by various
numbers of thrombospondin type one (TSP-1) motifs at
their C-terminal ends and the absence of transmembrane
and cytoplasmic domains.
The ADAMs group is comprised of more than 30
members (reviewed in [1, 2]). Proteinase activities have2 Enzyme Research
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Figure 1: Schematic of domain structure of ADAM proteinases. P: propeptide domain, M: metalloproteinase domain, D: disintegrin
domain, CR: cysteine-rich domain, EGF: EGF-like domain, T: transmembrane domain, C: cytoplasmic domain, SP: spacer domain, TS:
thrombospondin type I motif.
been demonstrated for ADAM8, 9, 10, 12, 15, 17, 19, 20,
21, 28, and 33, and these molecules contain a common
HEXGHXXGXXHD sequence. About 60% of the members
of this group are nonproteolytic ADAMs molecules.
Several ADAMs are expressed in multiple spliced forms.
Forexample, ADAM22,ADAM29,andADAM30havetwoto
three forms that vary in the lengths of theircytoplasmic tails,
although no functional diﬀerences in those isoforms have
been reported. In contrast, ADAM12 has two splice forms,
a membrane-bound form and a secreted form, which have
markedly diﬀerent activities.
ADAM17 is the most extensively investigated ADAM
proteinase and is known to release soluble TNF-α from
its membrane precursor, pro-TNF-α,w h i c hp e r m i t sT N F - α
paracrine signaling; thus, ADAM17 is also called TACE
(TNF-α-converting enzyme) [3]. ADAM17 plays a critical
role in the ectodomain shedding of many soluble proteins,
including TNF-α, TNF receptors I and II, TGF-α,H B - E G F ,
amphiregulin (AR), and interleukin-6 receptor (IL-6R). The
development of pharmaceutical inhibitors for ADAM17 has
focused on its role as a modulator of TNF-α in rheumatoid
arthritis[4].AsTNF-αisapotentproinﬂammatorycytokine,
ADAM17 inhibitors may be of particular utility in respira-
tory disease, ulcerative colitis, and other diseases. ADAM9
cleaves and releases EGF, HB-EGF, and ﬁbroblast growth fac-
tor receptor 2 IIIb. ADAM10 is involved in the ectodomain
sheddingofvarioussubstrates,includingadhesionmolecules
such as L1 cell adhesion molecule (L1-CAM) and CD44, E-
cadherin, and N-cadherin, IL-6R, CD30. ADAM12 is known
toparticipateintheectodomainsheddingofseveralpotential
substrates, including HB-EGF and EGF [5]. Moreover,
ADAM12 regulates transforming growth factor-β (TGF-β)
receptor traﬃcking. ADAM12 interacts with TGF-β receptor
and enhances TGF-β signaling bycontrolling thelocalization
of TGF-β receptors to early endosomes [6].
The ectodomain shedding of proHB-EGF actually pro-
duces two fragments, an extracellular fragment (HB-EGF),
and a remnant fragment (HB-EGF-C). Recently, promye-
locytic leukemia zinc ﬁnger (PLZF) was identiﬁed as a
binding protein of the cytoplasmic tail of proHB-EGF
[7]. PLZF is a transcriptional repressor of cyclin A and
suppresses cell growth by inhibiting entry or progression
into the S-phase of the cell cycle. Subsequent to proteolytic
cleavage of proHB-EGF, HB-EGF-C translocates from the
plasma membrane into the nucleus, which triggers nuclear
export of the transcriptional repressor PLZF. Suppression of
cyclin A and delayed entry into S-phase of cells expressing
PLZF can be reversed by the production of HB-EGF-C.
These results indicate that released HB-EGF-C functions as
an intracellular signal and coordinates cell cycle progression
with HB-EGF.
3.Involvement of ADAMsProteinasesin
SkinDiseases
3.1. Skin Cancer. S i n c eA D A M sc a nm e d i a t et h es h e d d i n g
of growth factors and regulate the adhesion and motility of
cells, ADAMs family proteinases are involved in signaling
events that are dysregulated in cancers and during tumor
progression [8]. In many types of cancers, ADAMs are
upregulated and several recent studies have highlighted
the potential of targeting ADAMs family members as a
new approach for antitumor therapy [9]. A schematic
summarizing the functions of ADAMs proteins is shown in
Figure 2.
3.1.1. Squamous Cell Carcinoma (SCC). G protein-coupled
receptors (GPCRs) have been shown to activate some
ADAMs proteinases and to transactivate epidermal growth
factor receptor (EGFR) [10]. Ultraviolet (UV) radiation of
skin cancer cells activates ADAMs and induces EGFR ligand
shedding and EGFR transactivation [11]. It is likely that UV
irradiation induces reactive oxygen species (ROS) genera-
tion, and that those ROS activate ADAM9 and ADAM17,
which thencleaveEGFRligands, particularlyAR.Thesoluble
form of AR subsequently binds to EGFR and can induce skin
cancer proliferation.
Overexpression of protein kinase Cε (PKCε)i nm o u s e
epidermis results in the rapid development of papilloma-
independent metastatic SCCs via the two-stage model of
carcinogenesis [12]. PKCε transgenic mice have elevated
serum TNF-α levels during skin tumor promotion by 12-
O-tetradecanoylphorbol-13-acetate (TPA). Since TNF-α is
linked to skin tumor promotion by TPA, this increase may
be linked to the development of metastatic SCC. TPA-
stimulated shedding of TNF-α could be completely pre-
vented in PKCε transgenic mice and isolated keratinocytes
by an ADAM17 inhibitor, TAPI-1. These results indicate
that PKCε signal transduction pathways to TPA-stimulated
TNF-α ectodomain shedding are mediated by ADAM17.
Injection of a TNF-α synthesis inhibitor during skin
tumor promotion completely prevented the development
of metastatic SCC in PKCε transgenic mice. The sum of
these results indicates that ADAM17 is involved in the
development of SCC in PKCε transgenic mice.Enzyme Research 3
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Figure 2: Physiological functions of ADAM proteinases in cancer.
3.1.2. Basal Cell Carcinoma (BCC). BCC is the most com-
m o nt y p eo fs k i nt u m o r .B C Cr a r e l ym e t a s t a s i z e sb u ti s
locally invasive and highly destructive. ADAM10, ADAM12,
and ADAM17 are increased at the peripheral tumor margin
comparedwithcentralareas ofBCCtumorcellnests.Expres-
sion of ADAM10 and ADAM12 is increased in the deep
margin of invading tumor cell nests. In contrast, ADAM17
is increased in superﬁcial BCC. ADAM10, ADAM12, and
ADAM17 show diﬀerent expression patterns in BCC his-
tologic subtypes, indicating their diﬀerent roles in the
pathogenesis of BCC [13].
3.1.3. Malignant Melanoma (MM). ADAM9, ADAM10,
ADAM12, ADAM15, and ADAM17 are overexpressed in
more than 10MM cell lines, and HB-EGF and TGF-α are
overexpressed in more than 10MM cell lines [11].
ADAM10 expression was signiﬁcantly elevated in
melanoma metastases compared with primary melanomas
[14]. Furthermore, expression of several components of the
Notch pathway, which can be cleaved by ADAM10, were
upregulated in MM compared with common melanocytic
nevi [15]. Down-regulation of ADAM10 with speciﬁc
siRNA resulted in the suppression of cell growth and the
reduced migration of MM cells. In addition, overexpression
of ADAM10 induced the migration of MM cells. Soluble
L1-CAM can induce cell migration through binding to
integrins. Elevated levels of L1-CAM in a metastatic
variant of an MM cell line suggest a role for L1-CAM in
tumor progression. Knockdown of L1-CAM reduced the
migration of MM cells and abrogated their chemoresistance
against cisplatin [14]. On the other hand, ADAM10 is the
major protease responsible for constitutive CD44 cleavage
from MM cells, and its expression can impair tumor cell
proliferation [16]. CD44 proteins are cell surface receptors
for hyaluronic acid (HA), a component of the extracellular
matrix that has multiple eﬀects on cell behavior. ADAM10,
ADAM17, and matrix metalloproteinase (MMP) 14 have
previously been implicated in the shedding of CD44 from
various tumor cells. In MM cells, ADAM10 and ADAM17
but not MMP14 are signiﬁcantly expressed in histological
sections. However, only ADAM10 but not ADAM17 is
involved in the constitutive shedding of native CD44 from
MM cells. HA promotes the proliferation of MM cells [17],
and soluble CD44 inhibits HA-stimulated proliferation of
melanoma cells in vitro and in vivo [18].
ADAM9 is detected in MM cells and in peritumoral
stromal ﬁbroblasts, while it is absent in ﬁbroblasts distal to
the tumor site. In contrast, in nevi, ADAM9 expression is
absent both in nevus cells and in stromal cells close to nevus
cell nests [19].
3.2. Wound Healing. Wound healing is a complex process
involving multiple cellular events, including cell prolifera-
tion, migration, and tissue remodeling. Members of the EGF
family, such as EGF, TGF-α, HB-EGF, AR, and their receptor
EGFR, are the most important factors in skin wound healing
[20–22]. TGF-α, AR, and HB-EGF are autocrine growth
factorsinnormalkeratinocytes[23,24],andbothTGF-αand
HB-EGF accelerate keratinocyte migration [25–28]. TNF-α
regulates keratinocyte migration in vivo and in vitro via a
MMP9 dependent pathway [29]. Blocking TNF-α function
inhibits keratinocyte migration. HB-EGF mRNA is rapidly
induced after scrape wounding of keratinocytes, with a
slight increase in TGF-α, AR, and blocking HB-EGF inhibits
keratinocyte migration [27, 28]. Therefore HB-EGF is the
predominant growth factor involved in the epithelialization
ofskinwoundhealinginvivoanditfunctionsbyaccelerating
keratinocyte migration. ADAM9, ADAM10, ADAM12, and
ADAM17 are considered candidate HB-EGF sheddases [30–
33], which are also expressed in keratinocytes [34–37].4 Enzyme Research
However it has been reported that ADAM9, ADAM10, and
ADAM17 reduce cell motility in cDNA-transfected HaCaT
cells [38].
Gene array data and immunohistochemistry from hu-
man venous reﬂux ulcers demonstrated that ADAM12 is
upregulated in the nonhealing edge of chronic skin ulcers
[39]. In addition, skin explants from ADAM12-deﬁcient
micerevealedasigniﬁcant increase inkeratinocytemigration
and proliferation compared to skin explants from wild-
type mice. Based on these ﬁndings, expression of ADAM12
in chronic wounds impairs wound healing through the
inhibition of keratinocyte migration and proliferation.
ADAM10representsthemajorE-cadherinsheddase[36].
ADAM10-mediated shedding of E-cadherin aﬀects epithelial
cell-cell adhesion as well as cell migration. The shedding
of E-cadherin by ADAM10 modulates the β-catenin sub-
cellular localization and downstream signaling. ADAM10
overexpression in epithelial cells increases the expression
of the β-catenin downstream gene cyclin D1 in a dose-
dependentmannerandenhancescellproliferation.ADAM10
is also involved in the cleavage of CXC-chemokine ligand 16
(CXCL16), which is expressed as a transmembrane adhesion
molecule and can be released as a chemoattractant [40].
CXCL16 is expressed in epidermal keratinocytes and is
released into the wound exudate upon injury.
ADAM9 expression is increased during the ﬁrst 7 days
after-wounding in a mouse wound model [41]. ADAM9
knockout mice show accelerated wound repair compared
with control littermates. No changes in the inﬁltration of
inﬂammatory cellsintothewoundareaswereobserved.Since
nodiﬀerencesinproliferationareobservedinvivoorinvitro,
the increased migration of keratinocytes is responsible for
this eﬀect.
3.3. Inﬂammatory Skin Diseases
3.3.1.Psoriasis. Psoriasis isacommonhyperproliferativeand
chronic inﬂammatory skin disease, and it has been proposed
that TNF-α is involved in its pathogenesis [42]. Increased
concentrations ofTNF-αhavebeendetectedinpsoriatic skin
lesions [43, 44]. Previous reports have shown that TGF-α,
AR, and HB-EGF are overexpressed in psoriatic epidermis
[45–47]. Further, soluble p55 and p75 TNF receptors are
upregulated in synovial ﬂuid from patients with psoriatic
arthritis [48]. EGFR and its ligands are considered to be
the most important mechanism for the proliferation of
keratinocytes. So far, overexpression of ADAM10, ADAM12,
and ADAM17 has been demonstrated in psoriatic skin
[35, 49]. ADAM17 cleaves TNF-α and TNF receptors.
ADAM10, ADAM12, and ADAM17 are critically involved
in EGFR-ligand shedding including HB-EGF. By this mech-
anism, these sheddases may play a role in the regulation
of keratinocyte proliferation and inﬂammation. Levels of
ADAM17are elevated in peripheral blood mononuclear cells
of patients with active psoriasis (compared with healthy
subjects), are correlated with the plasma concentration of
soluble TNF receptor, with the severity of the disease, and
are decreased after treatment [50].
ADAM33 has been identiﬁed as a novel psoriasis suscep-
tibility gene [51]. This gene has been previously reported to
be linkedto asthma [52], which indicates thatADAM33con-
trols general eﬀects on dermal inﬂammation and immunity.
3.3.2. Eczema. Acuteeczema is an inﬂammatory skin disease
characterized by scaling, redness, and itching. In acute
eczema, small intraepidermal blisters may occur, which
is characterized by reduced cohesion of keratinocytes. E-
cadherin is a prime mediator of epithelial cell-to-cell
interactions [53]. In several inﬂammatory skin diseases,
such as psoriasis and pemphigus vulgaris, increased serum
levels of soluble E-cadherin have been described [54]. Many
cytokines, growth factors, and chemokines contribute to
the pathogenesis of inﬂammatory epithelial skin diseases.
Proinﬂammatory cytokines signiﬁcantly increased levels of
soluble E-cadherin in keratinocytes, which was abrogated
in the presence of an ADAM10 inhibitor. ADAM10 levels
increase in areas of blisters [55]. These ﬁndings indicate
that inﬂammatory responses are able to activate ADAM10-
mediated proteolysis of E-cadherin in keratinocytes.
3.4. Pigmentary Disorders. The signaling activated by the
Kit ligand (Kitl), also referred to as stem cell factor (SCF),
and its receptor KIT (membrane-bound KIT; m-KIT) plays
an important role in melanocyte development, survival,
proliferation, and melanogenesis [56]. Kitl is synthesized as
a transmembrane protein and is processed to produce the
soluble secreted form Kitl. Alternative splicing generates two
Kitl RNA transcripts that encode two cell-associated Kitl
proteins, Kitl1, and Kitl2. Membrane-bound KIT protein
(m-KIT) is expressed as a transmembrane protein and has
a tyrosine kinase domain [57]. A cleaved, soluble product
of KIT, the soluble form of KIT (s-KIT), exists and has an
ability to bind SCF, and functions as a decoy receptor to
inhibit SCF/m-KIT signaling [58]. Mutations in the human
gene encodingKITresults inpiebaldism, a congenicdisorder
that is characterized by amelanotic patches on acral and/or
ventral skin surfaces [59]. Intradermal injection of SCF
enhances the number, size, and dendricity of melanocytes
in normal human skin xenografts, whereas interruption
of SCF binding to its receptor m-KIT decreases these
parameters [60]. UVB radiation augments the expression
of membrane-bound SCF in epidermal keratinocytes, and
injection of a KIT-inhibitory antibody abolishes the UVB-
induced increase in pigmentation in guinea pig skin [61].
SCF expression is increased in epidermal lentigo seniles [62].
SCF secreted by dermal ﬁbroblasts stimulates melanocytes
located in the epidermis overlying dermatoﬁbroma [63].
s-KIT has been detected in vivo in human serum and
plasma, and levels of s-KIT are increased in the sera
of patients with mastocytosis and correlates with disease
severity [64]. Additionally, the amount of s-KIT in the
serum correlates with graft-versus-host disease following
bone marrow transplantation [65]. Both ADAM17 and
ADAM19 aﬀect Kitl1 shedding in diﬀerent ways: ADAM17
is the major sheddase for Kitl1 and Kitl2, while ADAM19
reduces ADAM17-dependentphorbol-ester-stimulated Kitl1Enzyme Research 5
Table 1: Principal ADAMs proteinases involved in skin diseases.
ADAM substrate Pathology association
ADAM9 HB-EGF, EGF, Collagen XVII Cancer, Wound healing
ADAM10 E-cadherin, N-cadherin, CD44, EGF, HB-EGF, L1-CAM, CXCL16
Collagen XVII Cancer, Wound healing, Psoriasis,Eczema
ADAM12 EGF, HB-EGF Cancer, Wound healing, Psoriasis
ADAM17 TNF-α, TNFR, TGF-α, HB-EGF, AR, Collagen XVII, KIT, SCF Cancer, Migration, Psoriasis,Melanogenesis,SSc
ADAM33 Psoriasis
ectodomain shedding [66]. The production of s-KIT is
enhanced by an ADAM17 activator in melanocytes, and the
ADAM17 activator-induced production of s-KIT abolishes
SCF-induced melanogenesis [67]. Moreover, melanogenesis
is signiﬁcantly suppressed by the addition of an ADAM17
activator, whereas TAPI-1,an inhibitorofADAM17,isfound
to signiﬁcantly stimulate melanin synthesis in a 3D skin
model [67].
The melanocortin-1 receptor (MC1R) is a key regulator
of pigmentation in mammals and is tightly linked to an
increased risk of skin cancers, including melanoma, in
humans [68, 69]. Agouti signal protein (ASP) antagonizes
MC1R function, and is also associated with increased risk
of skin cancer [70]. Many genes that are upregulated by
ASPare involved in morphogenesis, cell adhesion, and extra-
cellular matrix-receptor interactions. Microarray analysis
indicates that ASP up-regulates several ADAM family genes
such as ADAM11, ADAM12, ADAM19, and ADAM23 in
melanocytes [71]. However the precise roles of these ADAM
proteinases on melanocytes remain unclear.
Color loci in mammals are genetic loci in which muta-
tions can aﬀect pigmentation of the hair, skin, and/or eyes.
In mice, over 800 phenotypic alleles are now known, at
more than 200 identiﬁed color loci [72]. In the ADAMs
family, ADAM17 and ADAMTS20 are known to be involved
in regulating pigmentation. ADAM17 knockout mice reveal
a disorganized distribution and structure of hair follicles,
which contain hairs with irregular pigment deposition [73].
A defect of ADAMTS20 is the cause of the belted (bt)w h i t e -
spotting mutation. It presents as a mostly pigmented mouse
except for a region proximal to the hindlimbs that appears as
aw h i t eb e l t[ 74]. ADAMTS20 is a secreted metalloprotease
which shows a highly dynamic pattern of expression in the
developing embryo that generally precedes the appearance
of melanoblasts, and is not expressed in the migrating cells.
It has been suggested that the ADAMTS20 proteinase plays
a role in the regulation of cell migration [74]. In humans,
ADAM17 and ADAMTS20 are also known to be candidate
genes that regulate pigmentation in East Asians [75].
3.5. Others
3.5.1. UV Radiation. UV radiation is clearly an important
environmental factor in human skin carcinogenesis. ADAMs
family proteinases are involved in regulating these signaling
pathways. UVA and UVB up-regulate ADAM17 mRNA
expression in immortalized keratinocyte HaCaT cells [76].
A low, nonlethal dose of UVA (1–4J/cm2) induces a dose-
dependent EGFR activation, cyclin D1 accumulation, and
cell cycle progression in HaCaT cells [77]. Knockdown
of ADAM17 blocks UVA-induced EGFR activation and
cell cycle progression, which demonstrates that ADAM17
mediates the EGFR/cyclin D1 pathway and cell cycle pro-
gression to the S phase induced by UVA radiation [77].
UVC also induces EGFR phosphorylation in melanocytes
and keratinocytes, which is inhibited by a broad spectrum
metalloproteinase inhibitor, BB94 [11]. AR is required for
UV-induced EGFR activation in SCC-9 cells, which depends
on ADAM9 and ADAM17.
3.5.2. Systemic Sclerosis. Systemic sclerosis (SSc) is a disease
characterized by progressive ﬁbrosis of multiple systems
including the skin. Elevated serum concentrations of the
soluble TNF receptor p55 and TNF-α are known to cor-
relate with the severity of SSc [78–80]. Up-regulation of
ADAM17 was observed in peripheral monocytes of patients
with early SSc [81]. Furthermore, the ADAM17 inhibitor,
TAPI-1, signiﬁcantly suppressed skin sclerosis induced by
bleomycin and reduced ﬁbrogenic cytokines [82]. These
ﬁndings indicate that ADAM17 could be a new target for the
therapy of SSc.
3.5.3. Collagen XVII. Collagen XVII (also called BP180 or
BPAG2) is a hemidesmosomal adhesion component in the
skin and mucosa [83]. Mutations in the COL17A1 gene are
associated with junctional epidermolysis bullosa, a genetic
skin blistering disease [84]. Patients with bullous pem-
phigoid and related autoimmune bullous dermatoses have
tissue-bound and circulating autoantibodies targeting colla-
gen XVII. Collagen XVII is an epithelial adhesion molecule
and is proteolytically released from the membrane via the
action of several ADAM proteases. ADAM9, ADAM10, and
ADAM17 are known to be collagen XVII sheddases [38, 85].
4.ConcludingRemarks
The currentstatusand futurepotentialofADAMsproteinase
activitiesintheﬁeldsofcutaneousbiologyandskindisorders
were discussed in this paper, and the functions of relevant
ADAMs proteinases are summarized in Table 1.Ab e t t e r
understanding of the regulatory mechanisms and physiolog-
ical functions of ADAMs proteinases in human skin may
generate novel targets for the diagnosis and/or therapeutics
of skin diseases.6 Enzyme Research
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